Mabion Temettü

Temettü kriter kontrolleri 0/6

Mabion does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Geri Alım Getirisi

Toplam Hissedar Getirisin/a
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 24
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit

Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth

Nov 28
Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts

Jun 02
Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts

Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?

Jul 09
Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?

Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News

Jun 04
Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News

Is Mabion (WSE:MAB) Using Too Much Debt?

Dec 22
Is Mabion (WSE:MAB) Using Too Much Debt?

Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

Sep 11
Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?

Feb 24
How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if MAB's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if MAB's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Mabion Piyasaya Karşı Temettü Getirisi
MAB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (MAB)n/a
Pazarın Alt %25'i (PL)2.8%
Pazarın En İyi %25'i (PL)8.0%
Sektör Ortalaması (Biotechs)1.5%
Analist tahmini (MAB) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate MAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate MAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate MAB's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as MAB has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin